Study shows drug effectiveness in reducing glucocorticoid-induced bone loss

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect—they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent. An alternative treatment option now appears promising, according to results of an international study published in the journal […]

Continue reading »

Study reveals large differences in drug prescriptions for newborns between NICUs

Little is known concerning how extensively drugs are prescribed to newborns in different neonatal intensive care units (NICUs). A new British Journal of Clinical Pharmacology study of nearly 1,500 newborns admitted during 12 months to four different NICUs in The Netherlands found that drug use varies widely. Cardiovascular and nervous system drugs were most often prescribed off-label in relation to […]

Continue reading »

Drug reduces size of some lung cancer tumors, relapse rate after surgery

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients. The research teams at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Johns Hopkins Sidney Kimmel […]

Continue reading »

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple

A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary […]

Continue reading »

Novel drug shows promise against acute myeloid leukemia

In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and […]

Continue reading »

Researchers define target and mechanism of antibacterial drug fidaxomicin (Dificid)

A team of Rutgers University and international scientists has determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC “urgent threat” bacterial pathogen Clostridium difficile (C. diff) and currently is one of two front-line drugs for treatment of C. diff. Fidaxomicin also exhibits potent antibacterial activity […]

Continue reading »
1 4 5 6